I'll research COR (Cencora) before writing the preview. Let me start by gathering recent filings, earnings materials, and news.Let me read the most recent earnings materials and check for the latest 10-Q and news.Now let me gather recent news, stock price performance, and any relevant peer/sector context ahead of the report.Let me check the Q3 earnings date announcement, recent news, and the prior-year Q3 for comparison.Let me pull the prior-year Q3 (fiscal 2025 Q3) release for the year-over-year comparison baseline.Let me get sector/policy context and any consensus estimates.# Cencora (COR) — Fiscal 3Q26 Earnings Preview Report date: Wednesday, August 5, 2026 (before market open); call at 8:30 a.m. ET Quarter: Fiscal Q3 2026 (ended June 30, 2026)
Cencora heads into its June-quarter print with a fully rebuilt stock price but a higher bar. Shares cratered ~17% on the May 6 (Q2) report—from ~$306 to ~$253—not on earnings (which beat and drove a guidance raise) but on a revenue guidance cut. Since then the stock has round-tripped all the way back to ~$306 by August 4. So the market has forgiven the revenue-optics scare; the question now is whether operating income momentum and the back-half ramp management promised are actually showing up. This is also new CFO Eva Boratto's first earnings call (Jim Cleary retired), which adds a communication/credibility wrinkle.
On the Q2 call, CFO Jim Cleary was unusually specific about the June quarter cadence:
| Metric | Q3 FY25 (actual) | Q3 FY26 implied |
|---|---|---|
| Adjusted EPS | $4.00 | ~$4.28–$4.36 (high-single-digit growth) |
| Revenue | $80.7B (+8.7%) | Slower; growth compressed by WAC cuts, brand conversions, GLP-1 |
| Net interest expense | $81.8M | ~$140M |
| Adj. tax rate | 20.7% | ~20% (FY guide) |
| Diluted shares | 195.2M | <195.5M (buyback resuming) |
For context: H1 FY26 adjusted EPS was $8.83 ($4.08 in Q1 + $4.75 in Q2). The full-year guide midpoint (~$17.78) implies ~$8.95 in H2, which is heavily back-loaded to Q4.
| FY26 Guidance | Current | FY25 Actual |
|---|---|---|
| Revenue growth | 4–6% (cut from 7–9%) | $321.3B |
| — U.S. Healthcare | 4–6% | $285.0B |
| — International | 8–10% (as-reported) | $28.3B |
| Adjusted operating income growth | 12–14% | $4.2B |
| — U.S. Healthcare OI | 14–16% | $3.3B |
| — International OI | 5–8% | $588M |
| Adjusted diluted EPS | $17.65–$17.90 | $16.00 |
| Net interest expense | ~$485M | $292M |
| Adj. FCF | ~$3.0B | $3.0B |
Key nuance: the Q2 revenue cut was not an earnings cut. Management stressed COR guides on operating income, and the revenue misses (manufacturer WAC price reductions, faster brand→biosimilar conversions at a large mail-order customer, slower GLP-1 growth) are low-margin activities with little OI impact. Watch whether they can raise EPS/OI guidance for a fourth straight quarter — H1 tracked well, but the Q4-weighting leaves less room for a big Q3 raise.
1. U.S. Healthcare Solutions operating income (the whole ballgame). Q2 core OI growth was ~7% ex-OneOncology/ex-lost customer, held back by ~$10M weather and ~$10M COVID-vaccine headwinds that management called transitory (and said rebounded in March/April). Q3 should show cleaner underlying trends plus a full quarter of OneOncology. But remember Q3 is comping against a monster +29.1% US OI print from a year ago — the growth rate will look optically soft even if the dollars are fine.
2. The interest-expense drag. Don't confuse strong OI growth with weak EPS growth — the ~$58M YoY interest step-up is the culprit, and it's known. Focus on OI and the deleveraging progress ($1.3B of term-loan paydown planned this year; $500M+ done at Q2).
3. Revenue optics vs. margin reality. Expect continued commentary on (a) GLP-1 deceleration (a 5-pt growth delta ≈ ~$2B revenue), (b) brand→biosimilar conversions at the large mail-order customer (revenue hit, negligible profit hit — and actually margin-accretive to the mix), and (c) WAC price reductions. Management's biosimilar framing matters: Part D conversions leave the channel (expected, low profit), while Part B biosimilar conversions are incrementally positive to COR and its physician practices.
4. International / World Courier. Global specialty logistics posted two consecutive quarters of OI growth into Q2, against an easy comp (Intl OI fell 12.9% in Q3 FY25). A third quarter of growth would reinforce the turnaround thesis; watch for volume growth, not just price/FX.
5. Capital return & the buyback restart. COR announced resumption of opportunistic repurchases — $1B by calendar year-end. Watch the pace and whether they lean in given the stock's May dip. Dividend was $0.60/quarter as of Q2.
6. Portfolio reshaping. Track the MWI Animal Health / Covetrus merger (MWI now "held for sale," which is inflating the "Other" segment OI via suspended depreciation), the EyeSouth retina tuck-in into RCA (not in FY26 guide), and OneOncology + RCA MSO integration synergies.
7. New CFO's tone. Eva Boratto's first call — listen for any reaffirmation/reframing of the long-term algorithm (7–10% organic OI growth, +3–4% from capital deployment, 10–14% EPS growth) and any changes to disclosure (several analysts have pushed for Part B vs. Part D profit-mix visibility).
8. Policy overhang. Drug-pricing/tariff dynamics (MFN, potential pharma tariffs, Medicare drug-negotiation changes) remain a sector-wide macro overhang for distributors, even if direct P&L impact is limited. Any framing here could move the group (MCK/CAH).
Going in, Q3 is set up to be the "quiet" quarter of FY26 — deliberately so. Management pre-committed to only high-single-digit EPS growth (interest-expense-driven), with the real acceleration saved for Q4 as it laps the oncology-customer loss and OneOncology accretion peaks. With the stock having fully recovered its post-Q2 drop, the risk is asymmetric: an in-line print with reaffirmed (not raised) guidance may underwhelm a re-rated stock, while the bull case rests on clean core U.S. OI trends, a fourth consecutive OI/EPS guidance raise, continued World Courier momentum, and a confident debut from the new CFO. Revenue will again look soft — but that's the wrong number to fixate on; operating income and the credibility of the Q4 ramp are what matter.
Note: figures above are drawn from Cencora's fiscal Q2 2026 and Q3 2025 earnings releases/calls and management's stated Q3 FY26 cadence guidance; "implied" Q3 EPS is my estimate from management's high-single-digit growth commentary, not a published consensus.